全文获取类型
收费全文 | 6419篇 |
免费 | 272篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 118篇 |
妇产科学 | 311篇 |
基础医学 | 643篇 |
口腔科学 | 206篇 |
临床医学 | 494篇 |
内科学 | 1708篇 |
皮肤病学 | 86篇 |
神经病学 | 373篇 |
特种医学 | 324篇 |
外科学 | 1179篇 |
综合类 | 25篇 |
一般理论 | 1篇 |
预防医学 | 209篇 |
眼科学 | 339篇 |
药学 | 238篇 |
中国医学 | 4篇 |
肿瘤学 | 434篇 |
出版年
2024年 | 6篇 |
2023年 | 69篇 |
2022年 | 126篇 |
2021年 | 195篇 |
2020年 | 116篇 |
2019年 | 175篇 |
2018年 | 225篇 |
2017年 | 118篇 |
2016年 | 167篇 |
2015年 | 164篇 |
2014年 | 254篇 |
2013年 | 365篇 |
2012年 | 497篇 |
2011年 | 586篇 |
2010年 | 361篇 |
2009年 | 356篇 |
2008年 | 489篇 |
2007年 | 547篇 |
2006年 | 497篇 |
2005年 | 440篇 |
2004年 | 339篇 |
2003年 | 260篇 |
2002年 | 197篇 |
2001年 | 35篇 |
2000年 | 16篇 |
1999年 | 15篇 |
1998年 | 37篇 |
1997年 | 20篇 |
1996年 | 22篇 |
1995年 | 17篇 |
1994年 | 9篇 |
1993年 | 5篇 |
1992年 | 9篇 |
1990年 | 2篇 |
1989年 | 7篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有6771条查询结果,搜索用时 15 毫秒
91.
Doundoulakis Ioannis Gavriilaki Maria Tsiachris Dimitris Arsenos Petros Antoniou Christos-Konstantinos Dimou Smaro Soulaidopoulos Stergios Farmakis Ioannis Akrivos Evangelos Stoiloudis Panagiotis Notas Konstantinos Kimiskidis Vasilios K. Giannakoulas George Paraskevaidis Stylianos Gatzoulis Konstantinos A. Tsioufis Konstantinos 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2022,36(5):951-958
Cardiovascular Drugs and Therapy - Atrial high-rate episodes (AHREs) recorded with cardiac implantable electronic devices (CIEDs) have been associated with the development of clinical atrial... 相似文献
92.
Brandon N. Nicolay Paul S. Danielian Filippos Kottakis John D. Lapek Jr Ioannis Sanidas Wayne O. Miles Mantre Dehnad Katrin Tsch?p Jessica J. Gierut Amity L. Manning Robert Morris Kevin Haigis Nabeel Bardeesy Jacqueline A. Lees Wilhelm Haas Nicholas J. Dyson 《Genes & development》2015,29(17):1875-1889
93.
Urological complications,vesicoureteral reflux,and long‐term graft survival rate after pediatric kidney transplantation
下载免费PDF全文
![点击此处可从《Pediatric transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Fabio C. M. Torricelli Andreia Watanabe Affonso C. Piovesan Ioannis M. Antonopoulos Elias David‐Neto William C. Nahas 《Pediatric transplantation》2015,19(8):844-848
To describe a single‐center experience with kidney transplantation and then study some donor and recipient features that may impact on graft survival and urological complication rates. We reviewed our database searching for pediatric patients who underwent kidney transplantation from August 1985 through November 2012. Preoperative data and postoperative complications were recorded. Graft survival rates were analyzed and compared based on the type of donor, donor's age from deceased donors, and recipients' ESRD cause. Kaplan–Meier curves with log rank and Wilcoxon tests were used to perform the comparisons. There were 305 pediatric kidney transplants. The mean recipient's age was 11.7 yr. The mean follow‐up was 11.0 yr. Arterial and venous thrombosis rates were 1.6% and 2.3%, respectively, while urinary fistula and symptomatic vesicoureteral reflux were diagnosed in 2.9% and 3.6% of cases, respectively. Deceased kidney transplantation had a lower graft survival rate than living kidney transplantation (log rank, p = 0.005). Donor's age (p = 0.420) and ESRD cause (p = 0.679) were not significantly related to graft survival rate. In long‐term follow‐up, type of donor, but not donor's age, impacts on graft survival rate. ESRD cause has no impact on graft survival rate, showing that well‐evaluated recipients may have good outcomes. 相似文献
94.
Koutroubakis IE Petinaki E Dimoulios P Vardas E Roussomoustakaki M Maniatis AN Kouroumalis EA 《International journal of colorectal disease》2003,18(3):254-259
BACKGROUND AND AIMS: Initiation of a fibrotic process has been suggested as part of the intestinal response to chronic inflammation in inflammatory bowel disease. YKL-40 has been proposed as a new serum marker of fibrosis. We studied compared the serum levels of YKL-40 in patients with ulcerative colitis or Crohn's disease with inflammatory and healthy controls. PATIENTS AND METHODS: YKL-40 serum levels were measured in 179 patients with inflammatory bowel disease (94 ulcerative colitis, 85 Crohn's disease), in 23 with intestinal inflammation of other causes, and 70 matched healthy controls using a commercially available enzyme-linked immunosorbent assay. YKL-40 levels were assessed in terms of disease activity, type and localization. RESULTS: Mean serum YKL-40 levels were 102.6+/-82.7 ng/ml in ulcerative colitis patients and 112.2+/-83.7 ng/ml in Crohn's disease patients, significantly higher than in healthy controls (64.1+/-21.4 ng/ml) but not significantly different from inflammatory controls (77.8+/-23.1 ng/ml). Disease activity and C-reactive protein levels were significantly correlated with YKL-40 levels in both ulcerative colitis and Crohn's disease. Crohn's disease patients with ileum localization had significantly higher YKL-40 levels than those with ileocolonic or colonic disease. Patients with stenotic disease had mean YKL-40 levels not significantly different than those with nonstenotic disease. CONCLUSION: Serum levels of YKL-40 are increased in patients with inflammatory bowel disease, and this is associated with the inflammatory process rather than with the degree of fibrosis. 相似文献
95.
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection 总被引:5,自引:0,他引:5
Mulherin SA O'Brien TR Ioannidis JP Goedert JJ Buchbinder SP Coutinho RA Jamieson BD Meyer L Michael NL Pantaleo G Rizzardi GP Schuitemaker H Sheppard HW Theodorou ID Vlahov D Rosenberg PS;International Meta-Analysis of HIV Host Genetics 《AIDS (London, England)》2003,17(3):377-387
OBJECTIVE: To examine temporal variation in the effects of CCR5-Delta32 and CCR2-64I chemokine receptor gene polymorphisms on HIV-1 disease progression. DESIGN: Pooled analysis of individual patient data from 10 cohorts of HIV-1 seroconverters from the United States, Europe, and Australia. METHODS: We studied HIV-1 seroconverters of European (n = 1635) or African (n = 215) ancestry who had been genotyped for CCR5-Delta32 and CCR2-64I. We used Cox proportional hazards models with time-varying coefficients to determine whether the genetic protection against AIDS (1987 case definition) and death varied with time since seroconversion. RESULTS: Protection against AIDS conferred by CCR5-Delta32 held constant at a 31% (RH 0.69, 95% CI 0.54, 0.88) reduction in risk over the course of HIV-1 infection, whereas protection against death held constant at a 39% reduction in risk (RH 0.61, 95% CI 0.45, 0.88). When the period from AIDS to death was isolated, the survival benefit of CCR5-Delta32 diminished 2 years after AIDS. Protection against AIDS conferred by CCR2-64I was greatest early in the disease course. Compared with individuals without CCR5-Delta32 or CCR2-64I, individuals with one or two copies of CCR2-64I had a 58% lower risk of AIDS during the first 4 years after seroconversion (RH 0.42, 95% CI 0.23, 0.76), a 19% lower risk during the subsequent 4 years (RH 0.81, 95% CI 0.59, 1.12), and no significant protection thereafter. CONCLUSION: The protection against AIDS provided by CCR5-Delta32 is continuous during the course of infection. In contrast, the protection provided by CCR2-64I is greatest early in the course of infection. 相似文献
96.
97.
98.
99.
100.
Effie Polyzogopoulou Pinelopi Amoiridou Theodore P Abraham Ioannis Ventoulis 《World journal of gastroenterology : WJG》2022,28(47):6662-6688
In recent years, humanity has been confronted with a global pandemic due to coronavirus disease 2019 (COVID-19), which has caused an unprecedented health and economic crisis worldwide. Apart from the respiratory symptoms, which are considered the principal manifestations of COVID-19, it has been recognized that COVID-19 constitutes a systemic inflammatory process affecting multiple organ systems. Across the spectrum of organ involvement in COVID-19, acute liver injury (ALI) has been gradually gaining increasing attention by the international scientific community. COVID-19 associated liver impairment can affect a considerable proportion of COVID-19 patients and seems to correlate with the severity of the disease course. Indeed, COVID-19 patients hospitalized in the intensive care unit (ICU) run a greater risk of developing ALI due to the severity of their clinical condition and in the context of multi-organ failure. The putative path ophysiological mechanisms of COVID-19 induced ALI in ICU patients remain poorly understood and appear to be multifactorial in nature. Several theories have been proposed to explain the occurrence of ALI in the ICU setting, such as hypoperfusion and ischemia due to hemodynamic instability, passive liver congestion as a result of congestive heart failure, ischemia-reperfusion injury, hypoxia due to respiratory failure, mechanical ventilation itself, sepsis and septic shock, cytokine storm, endotheliitis with concomitant coagulopathy, drug-induced liver injury, parenteral nutrition and direct cytopathic viral effect. It should be noted that no specific therapy for COVID-19 induced ALI exists. Therefore, the therapeutic approach lies in preventive measures and is exclusively supportive once ALI ensues. The aim of the current review is to scrutinize the existing evidence on COVID-19 associated ALI in ICU patients, explore its clinical implications, shed light on the underlying pathophysiological mechanisms and propose potential therapeutic approaches. Ongoing research on the particular scientific field will further elucidate the pathophysiology behind ALI and address unresolved issues, in the hope of mitigating the tremendous health consequences imposed by COVID-19 on ICU patients. 相似文献